Clinical studies of testosterone for the treatment of age-related conditions
in men aged 65 years or older should go forward, according to a committee
of the Institute of Medicine of the National Academies. But the group recommended
that only a limited number of participants should be included, and that trials
should focus on determining the efficacy and potential benefits of the therapy.
The committee said that a larger trial to study long-term risks and
effectiveness should be initiated only if substantial benefits can be demonstrated
in initial, short studies. The committee's report also said that studies should
include only older men who are not at risk of developing prostate cancer,
who have been diagnosed as having low testosterone levels, and who have at
least one symptom that could be alleviated by therapy.
Hampton T. Autoantibodies Predict Lupus. JAMA. 2003;290(24):3186. doi:10.1001/jama.290.24.3186-a